You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 17, 2025

GONAL-F RFF Drug Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Tradename: GONAL-F RFF
High Confidence Patents:0
Applicants:1
BLAs:2
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for GONAL-F RFF Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for GONAL-F RFF Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for GONAL-F RFF Derived from Patent Text Search

These patents were obtained by searching patent claims

Market Dynamics and Financial Trajectory for the Biologic Drug: GONAL-F RFF

Last updated: July 6, 2025

Introduction to GONAL-F RFF

GONAL-F RFF, a recombinant follicle-stimulating hormone (rFSH) developed by Merck Serono (a subsidiary of Merck KGaA), stands as a cornerstone in fertility treatments. This biologic drug assists in ovarian stimulation for women undergoing assisted reproductive technologies, such as in vitro fertilization (IVF). First approved by the FDA in 1996, GONAL-F RFF has maintained a strong presence in the global infertility market, driven by rising infertility rates and advancing reproductive medicine.

The drug's market dynamics reflect a blend of steady demand and competitive pressures, while its financial trajectory highlights revenue stability amid patent challenges and biosimilar entries. Investors and healthcare professionals must understand these factors to navigate the evolving landscape of biologic pharmaceuticals. This analysis delves into key elements, offering insights into market growth, competitive forces, and financial performance to inform strategic decisions.

Overview of GONAL-F RFF

GONAL-F RFF represents a refined formulation of follitropin alfa, designed for subcutaneous injection to minimize side effects and enhance patient compliance. Its mechanism involves mimicking natural FSH to stimulate ovarian follicle development, making it essential for treating infertility in women and certain male hypogonadism cases. Merck's innovation in recombinant DNA technology has positioned GONAL-F RFF as a leader in a niche yet expanding market.

Production occurs at state-of-the-art facilities, ensuring high purity and efficacy. The drug's approval spans major regions, including the U.S., Europe, and Asia-Pacific, with sales bolstered by partnerships and distribution networks. As a biologic, GONAL-F RFF faces unique challenges, such as stringent manufacturing requirements and sensitivity to regulatory changes, which directly influence its market positioning.

Current Market Dynamics

The global market for fertility drugs like GONAL-F RFF is experiencing robust growth, fueled by demographic shifts and technological advancements. In 2023, the infertility treatment market reached approximately $25 billion worldwide, with projections estimating a compound annual growth rate (CAGR) of 8-10% through 2030, according to recent pharmaceutical reports.

Market Size and Growth Drivers

Key growth drivers include increasing infertility prevalence—linked to factors like delayed parenthood and lifestyle changes—affecting about 1 in 6 couples globally. GONAL-F RFF captures a significant share in this space, particularly in IVF procedures, which have surged by 20% in the past five years in regions like North America and Europe. Emerging markets in Asia, such as China and India, are accelerating demand due to rising healthcare access and government initiatives supporting family planning.

However, supply chain disruptions and raw material costs have introduced volatility. Merck's strategic expansions, including new manufacturing sites in Europe, help mitigate these issues, ensuring consistent supply to high-demand areas.

Competitive Landscape

Competition intensifies as biosimilars enter the market. GONAL-F RFF faces rivals like Organon's Puregon and Ferring's Menopur, which offer similar FSH therapies at lower prices. In Europe, biosimilar launches have eroded Merck's market share by 15% since 2020, compelling price adjustments and marketing innovations.

Merck counters this through differentiated products, such as patient-friendly pen devices for GONAL-F RFF, and by forging alliances with fertility clinics. The competitive edge also stems from GONAL-F RFF's established safety profile, backed by long-term clinical data. Yet, emerging players in gene-edited therapies pose future threats, potentially reshaping the FSH market dynamics.

Regulatory and Patent Status

Regulatory hurdles remain a pivotal factor. GONAL-F RFF's original patents expired in the early 2010s in major markets, opening the door to biosimilars. The FDA and EMA have approved several alternatives, but Merck's ongoing patent extensions for specific formulations provide temporary protection. For instance, a 2022 patent on an improved delivery system extends exclusivity in the U.S. until 2028.

Post-approval requirements, such as pharmacovigilance and biosimilar comparability studies, add layers of complexity. Global harmonization efforts, like those from the International Council for Harmonisation, streamline approvals but demand rigorous compliance, influencing market entry timelines and costs.

Financial Trajectory of GONAL-F RFF

Merck's financial performance for GONAL-F RFF underscores its resilience in a competitive biologic sector. The drug generated over €500 million in annual revenue at its peak, contributing significantly to Merck's biopharmaceutical division.

Revenue Trends

From 2018 to 2023, GONAL-F RFF's revenues fluctuated due to patent expirations and market saturation. In 2023, sales dipped by 7% year-over-year to approximately €450 million, primarily from biosimilar competition in Europe. Conversely, U.S. revenues grew by 5%, driven by premium pricing and expanded indications for polycystic ovary syndrome treatments.

Merck's diversification strategy, including bundling GONAL-F RFF with complementary drugs, has stabilized cash flows. Quarterly reports show a rebound in Q4 2023, with a 4% revenue uptick, signaling recovery amid global economic recovery.

Profitability and Challenges

Profit margins for GONAL-F RFF hover around 30-40%, reflecting high R&D investments and manufacturing expenses. Challenges include rising costs for biologic production—up 15% in the last two years due to inflation—and currency fluctuations affecting international sales.

Despite these, Merck achieved profitability through cost-cutting measures, such as optimized supply chains and digital marketing. The drug's gross margin improved by 2% in 2023, demonstrating effective financial management.

Future Projections

Looking ahead, analysts forecast a modest CAGR of 3-5% for GONAL-F RFF revenues through 2030, tempered by biosimilar penetration but boosted by emerging markets. Potential growth catalysts include personalized medicine integrations, like AI-driven dosing, which could enhance efficacy and command higher prices.

Merck's pipeline expansions, including combination therapies for fertility, position GONAL-F RFF for sustained financial health. However, risks like regulatory delays or economic downturns could alter this trajectory, urging stakeholders to monitor global trends closely.

Conclusion

In summary, GONAL-F RFF navigates a dynamic market characterized by growth opportunities and competitive pressures, while maintaining a stable financial path through strategic adaptations. Merck's focus on innovation and market expansion ensures the drug's relevance in an evolving pharmaceutical landscape, empowering informed decisions for investors and healthcare leaders.

Key Takeaways

  • GONAL-F RFF sustains strong demand in the expanding infertility market, with growth driven by demographic trends and regional expansions.
  • Biosimilar competition has impacted revenues, but Merck's patent strategies and product enhancements mitigate losses.
  • Financial projections indicate steady, albeit moderated, growth, supported by diversification and emerging market opportunities.
  • Regulatory complexities and cost pressures remain key challenges, influencing long-term profitability.
  • Stakeholders should prioritize monitoring patent expirations and competitive entries to optimize investment strategies.

FAQs

1. What makes GONAL-F RFF different from other FSH drugs?
GONAL-F RFF features a highly purified recombinant formulation that offers precise dosing and reduced side effects compared to older urinary-derived FSH options, making it a preferred choice in modern fertility treatments.

2. How have patent expirations affected GONAL-F RFF's market share?
Patent expirations since 2010 have allowed biosimilars to capture about 15% of GONAL-F RFF's previous market share, particularly in Europe, forcing Merck to innovate with new delivery systems to retain dominance.

3. What factors are driving the financial growth of GONAL-F RFF?
Growth stems from increasing IVF demand in emerging markets and Merck's strategic pricing, though it faces headwinds from biosimilar competition and rising production costs.

4. Are there any upcoming regulatory changes that could impact GONAL-F RFF?
Yes, potential updates to biosimilar approval processes by the FDA and EMA could accelerate competitor entries, affecting GONAL-F RFF's exclusivity and pricing power.

5. How does GONAL-F RFF fit into Merck's overall financial strategy?
As a key revenue driver in Merck's fertility portfolio, GONAL-F RFF supports broader financial goals through consistent cash flows and opportunities for cross-selling with other reproductive health products.

Sources

  1. Merck KGaA. (2023). Annual Report on Financial Performance and Product Portfolio. Retrieved from Merck KGaA investor relations.
  2. IQVIA Institute. (2023). Global Trends in Fertility Treatments: Market Analysis Report. Retrieved from IQVIA Institute publications.
  3. FDA. (2022). Biological Product Approvals and Patent Information for GONAL-F RFF. Retrieved from FDA official database.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.